Alzheimer's Disease
About Alzheimer's Disease
Alzheimer's Disease is a chronic neurodegenerative disease and is represented in 60-70% of cases of dementia. In 2015, there were approximately 29.8 million people worldwide living with AD. It affects around 6% of people aged 65+ years. There are currently no treatments to halt or reverse its progression. There is significant ongoing research to better understand and treat AD. IXICO has supported important AD research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies
Experience and capacity
- Experience and capacity to support all phases of AD clinical research from early to late phase studies. Scalable to studies that require the management and analysis of large numbers of data sets.
- Technology-enabled standardisation in imaging and wearables site set-up improves data quality and consistency in global multi-centre trials.
Imaging network
- Network of over 1,500 qualified imaging facilities with established connections to clinical research sites.
- Patient centricity: gaining insights into people living with Alzheimer’s disease coupled with training and technology improves recruitment, retention and support to trial participants.
Expert neuroradiology
- Team of expert Neuro-radiologists performing centralized, real time, standardised safety reads.
- Optimum solutions for delivery of data science including advanced MRI, PET, and wearable technology.
Collaboration
- Collaboration with International Consortia, academic institutions and global networks of Research Sites enables efficient and effective delivery of imaging and other data science.